文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

靶向蛋白磷酸酶治疗癌症免疫治疗和自身免疫性疾病。

Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.

机构信息

Department of Medicine, University of California, San Diego, CA, USA.

出版信息

Nat Rev Drug Discov. 2023 Apr;22(4):273-294. doi: 10.1038/s41573-022-00618-w. Epub 2023 Jan 24.


DOI:10.1038/s41573-022-00618-w
PMID:36693907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9872771/
Abstract

Protein phosphatases act as key regulators of multiple important cellular processes and are attractive therapeutic targets for various diseases. Although extensive effort has been dedicated to phosphatase-targeted drug discovery, early expeditions for competitive phosphatase inhibitors were plagued by druggability issues, leading to the stigmatization of phosphatases as difficult targets. Despite challenges, persistent efforts have led to the identification of several drug-like, non-competitive modulators of some of these enzymes - including SH2 domain-containing protein tyrosine phosphatase 2, protein tyrosine phosphatase 1B, vascular endothelial protein tyrosine phosphatase and protein phosphatase 1 - reigniting interest in therapeutic targeting of phosphatases. Here, we discuss recent progress in phosphatase drug discovery, with emphasis on the development of selective modulators that exhibit biological activity. The roles and regulation of protein phosphatases in immune cells and their potential as powerful targets for immuno-oncology and autoimmunity indications are assessed.

摘要

蛋白磷酸酶作为多种重要细胞过程的关键调节剂,是各种疾病有吸引力的治疗靶点。尽管人们已经投入了大量的精力用于磷酸酶靶向药物的发现,但早期针对竞争性磷酸酶抑制剂的探索受到了成药性问题的困扰,导致磷酸酶被污名化为难以成药的靶点。尽管存在挑战,但持续的努力已经导致了一些具有药物样性质的、非竞争性的这些酶的调节剂的鉴定,包括含 SH2 结构域的蛋白酪氨酸磷酸酶 2、蛋白酪氨酸磷酸酶 1B、血管内皮蛋白酪氨酸磷酸酶和蛋白磷酸酶 1,这重新激发了人们对磷酸酶治疗靶点的兴趣。在这里,我们讨论了磷酸酶药物发现的最新进展,重点介绍了具有生物活性的选择性调节剂的开发。评估了蛋白磷酸酶在免疫细胞中的作用和调节及其作为免疫肿瘤学和自身免疫疾病靶点的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9616/9872771/7fb7901ac515/41573_2022_618_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9616/9872771/14d0517a63df/41573_2022_618_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9616/9872771/7fb7901ac515/41573_2022_618_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9616/9872771/14d0517a63df/41573_2022_618_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9616/9872771/7fb7901ac515/41573_2022_618_Fig2_HTML.jpg

相似文献

[1]
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.

Nat Rev Drug Discov. 2023-4

[2]
Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs).

Anticancer Agents Med Chem. 2009-2

[3]
Protein tyrosine phosphatases in autoimmunity.

Annu Rev Immunol. 2008

[4]
Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.

Future Med Chem. 2010-10

[5]
Are other protein tyrosine phosphatases than PTPN22 associated with autoimmunity?

Semin Immunol. 2006-8

[6]
Targeting Tyrosine Phosphatases: Time to End the Stigma.

Trends Pharmacol Sci. 2017-6

[7]
Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies.

Cells. 2024-1-25

[8]
Protein tyrosine phosphatases: mechanisms of catalysis and regulation.

Curr Opin Chem Biol. 1998-10

[9]
The therapeutic potential of phosphatase inhibitors.

Curr Opin Chem Biol. 2009-6

[10]
Protein tyrosine phosphatases as potential therapeutic targets.

Acta Pharmacol Sin. 2014-10

引用本文的文献

[1]
PTPN22-CD45 dual phosphatase retrograde feedback enhances TCR signaling and autoimmunity.

Sci Adv. 2025-9-5

[2]
Pharmacological Targeting of DHHC9-Mediated STRN4 Palmitoylation to Suppress YAP-Driven Cancer Metastasis.

J Cell Mol Med. 2025-9

[3]
BRG1 inhibits glycolysis by promoting SHP1-mediated dephosphorylation of PKM2 in non-small cell lung cancer.

Oncogenesis. 2025-8-24

[4]
Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1/PP2A-mediated ERK1/2 dephosphorylation in hepatocellular carcinoma.

J Exp Clin Cancer Res. 2025-7-11

[5]
PTPN2 inhibits TG-induced ERS-initiated TNBC apoptosis through the mitochondrial pathway.

Sci Rep. 2025-6-6

[6]
The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy.

Cell Rep Med. 2025-5-20

[7]
PRL-3: unveiling a new horizon in cancer therapy.

Acta Pharmacol Sin. 2025-5-8

[8]
Targeting PD-1 post-translational modifications for improving cancer immunotherapy.

Cell Insight. 2025-4-10

[9]
Rare genetic variation in PTPRB is associated with central serous chorioretinopathy, varicose veins and glaucoma.

Nat Commun. 2025-5-3

[10]
Malignant JAK-signaling: at the interface of inflammation and malignant transformation.

Leukemia. 2025-5

本文引用的文献

[1]
Chemogenetic profiling reveals PP2A-independent cytotoxicity of proposed PP2A activators iHAP1 and DT-061.

EMBO J. 2022-7-18

[2]
Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.

Mol Cell Biol. 2022-3-17

[3]
The catalytic activity of TCPTP is auto-regulated by its intrinsically disordered tail and activated by Integrin alpha-1.

Nat Commun. 2022-1-10

[4]
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity.

Cancer Discov. 2022-3-1

[5]
Old and New Calcineurin Inhibitors in Lupus Nephritis.

J Clin Med. 2021-10-21

[6]
Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19.

JCI Insight. 2021-10-22

[7]
Proautoimmune Allele of Tyrosine Phosphatase, PTPN22, Enhances Tumor Immunity.

J Immunol. 2021-9-15

[8]
Systemic inhibition of PTPN22 augments anticancer immunity.

J Clin Invest. 2021-7-20

[9]
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Lancet. 2021-5-29

[10]
The Eyes Absent Proteins: Unusual HAD Family Tyrosine Phosphatases.

Int J Mol Sci. 2021-4-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索